Literature DB >> 9863863

Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy.

F P Kroon1, G F Rimmelzwaan, M T Roos, A D Osterhaus, D Hamann, F Miedema, J T van Dissel.   

Abstract

BACKGROUND: Highly active antiretroviral therapy (HAART) effectively suppresses replication of HIV and is accompanied by an increase in CD4+ T lymphocytes. Whether the increase in CD4+ T lymphocytes in the blood is a reflection of a reconstitution of the immune functions is unknown. We investigated the recovery of the humoral immune response during HAART after immunization with T-cell-dependent influenza vaccine.
METHODS: Forty-one men and three women infected with HIV and treated with HAART, and 15 healthy hospital staff members were immunized with trivalent influenza subunit vaccine. Antibody titres were determined by haemagglutination inhibiting assay in sera obtained before and 30 days after immunization. Lymphocyte subsets were determined in blood samples taken at the time of vaccination.
RESULTS: In all HIV-infected individuals, treatment with HAART caused a median reduction of 2.3 log10 in HIV-1 load. The median increase of CD4+ T lymphocytes after initiation of HAART was 170 x 10(6)/l. The antibody response to influenza antigens was proportional to the number of memory CD4+ T lymphocytes in the blood at the time of vaccination. When a group of patients and healthy controls with approximately similar CD4+ T-lymphocyte counts were considered, the antibody titres after vaccination for influenza strain H1N1 and influenza B did not differ between patients and controls (P=0.12). Vaccination of patients with a CD4+ T-lymphocyte count of < 200 x 10(6)/l (mean 85 x 10(6)/l) before the start of HAART and with a mean of 282 x 10(6)/l CD4+ T lymphocytes at the time of vaccination as a result of HAART, demonstrated a substantial antibody response whereas patients with a CD4+ T lymphocyte count of < 200 x 10(6)/l (mean 56 x 10(6)/l) not treated with HAART (historical controls), and vaccinated with a similar influenza vaccine, failed to induce an antibody response.
CONCLUSION: The present findings demonstrate a recovery of the humoral immune response to influenza antigens in HIV-infected individuals treated with HAART. This indicates that functional improvement of antigen specific CD4+ T helper cell reponses occurs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9863863     DOI: 10.1097/00002030-199817000-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  31 in total

Review 1.  Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.

Authors:  G R Kaufmann; J Zaunders; D A Cooper
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  Functional impairment of CD4 T cells despite normalization of T cell number in HIV.

Authors:  Kenneth S Knox; Richard B Day; Lisa M Kohli; Chadi A Hage; Homer L Twigg
Journal:  Cell Immunol       Date:  2006-10-30       Impact factor: 4.868

Review 3.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

4.  Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine.

Authors:  Anne B Kristensen; William N Lay; Fernanda Ana-Sosa-Batiz; Hillary A Vanderven; Vijaya Madhavi; Karen L Laurie; Louise Carolan; Bruce D Wines; Mark Hogarth; Adam K Wheatley; Stephen J Kent
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

5.  Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.

Authors:  M Medina-Ramírez; V Sánchez-Merino; S Sánchez-Palomino; A Merino-Mansilla; C B Ferreira; I Pérez; N González; A Alvarez; J M Alcocer-González; F García; J M Gatell; J Alcamí; E Yuste
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

6.  Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy.

Authors:  Raiees Andrabi; M A Makhdoomi; Rajesh Kumar; Manju Bala; Hilal Parray; Arjun Gupta; Ankita Kotnala; Velpandian Thirumurthy; Kalpana Luthra
Journal:  J Clin Immunol       Date:  2014-03-29       Impact factor: 8.317

7.  Latent reservoirs of HIV: obstacles to the eradication of virus.

Authors:  T W Chun; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

8.  CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies.

Authors:  Sharat Srinivasula; Erin Gabriel; Insook Kim; Paula DeGrange; Alexis St Claire; Candace Mallow; Robert E Donahue; Chang Paik; H C Lane; Michele Di Mascio
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

9.  The γδ T-cell receptor repertoire is reconstituted in HIV patients after prolonged antiretroviral therapy.

Authors:  Suchita Chaudhry; Cristiana Cairo; Vanessa Venturi; C David Pauza
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

10.  Changes in the socio-demographics, risk behaviors, clinical and immunological profile of a cohort of the Puerto Rican population living with HIV: an update of the Retrovirus Research Center (1992-2008).

Authors:  Christine Miranda; Diana M Fernandez; Raul O Ramon; Miriam Velázquez; Angel M Mayor; Robert F Hunter-Mellado
Journal:  Bol Asoc Med P R       Date:  2010 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.